Evidence map›Paper›PMID 30482774›Full record

ArticleCancer research2019

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 395 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
395citing papers in PubMed, 4 pooled it
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

395 citing papers in PubMed, 4 syntheses or guidelines pooled it, 573 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. TALAVE in Breast Cancer:bioRxiv : the preprint server for biology · 2026
    Article

335 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jianfeng ShenDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wei ZhaoDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhenlin JuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lulu WangDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yang PengDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Marilyne LabrieDepartment of Cell, Developmental & Cancer Biology, Oregon Health and Science University Knight Cancer Institute, Portland, Oregon.
Timothy A YapDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gordon B MillsDepartment of Cell, Developmental & Cancer Biology, Oregon Health and Science University Knight Cancer Institute, Portland, Oregon. gpeng@mdanderson.org millsg@ohsu.edu.
Guang PengDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas. gpeng@mdanderson.org millsg@ohsu.edu.
The University of Texas MD Anderson Cancer Center · USOregon Health & Science University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9M
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6M
Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinomaR01CA181663 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Guang Peng · 2016 to 2026
$3.1M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA181663NCI NIH HHS U01 CA217842
6 · The paper itself

Abstract

PARP inhibitors (PARPi) have shown remarkable therapeutic efficacy against

Indexed as

AnimalsAntibodiesAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCell Line, TumorColorectal NeoplasmsDNADrug SynergismFemaleGenes, BRCA1Genes, BRCA2HumansMembrane ProteinsMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutAntibodiesB7-H1 AntigenDNAMembrane ProteinsPoly(ADP-ribose) Polymerase InhibitorsSTING1 protein, humanSting1 protein, mouseSTING Protein

Identifiers

PMID30482774
PMCPMC6588002
OpenAlexW2802480234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.